U.S. stock futures were mostly higher this morning, with the Dow futures gaining around 0.1% on Tuesday.
Shares of Acelyrin, Inc. (NASDAQ:SLRN) fell sharply in today's pre-market trading.
ACELYRIN announced additional Phase 2 data and the Phase 3 program design for lonigutamab in Thyroid Eye Disease.
Acelyrin shares tumbled 15.4% to $2.95 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
Now Read This:
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
